• Best Practices New Normal
  • Digital Dentistry
  • Data Security
  • Implants
  • Catapult Education
  • COVID-19
  • Digital Imaging
  • Laser Dentistry
  • Restorative Dentistry
  • Cosmetic Dentistry
  • Periodontics
  • Oral Care
  • Evaluating Dental Materials
  • Cement and Adhesives
  • Equipment & Supplies
  • Ergonomics
  • Products
  • Dentures
  • Infection Control
  • Orthodontics
  • Technology
  • Techniques
  • Materials
  • Emerging Research
  • Pediatric Dentistry
  • Endodontics
  • Oral-Systemic Health

Convergent Dental announces FDA clearance of osseous tissue procedures for Solea at ADA 2015

Article

Convergent Dental, Inc., a privately held dental device company, announced Solea®, the first FDA-cleared CO2 9.3-micron dental laser for hard and soft tissue, has also been cleared to perform osseous tissue procedures.

Convergent Dental, Inc., a privately held dental device company,  announced  Solea®, the first FDA-cleared CO2 9.3-micron dental laser for hard and soft tissue, has also been cleared to perform osseous tissue procedures.

With this expanded indication, Solea reportedly can be used to treat not only cavity preparations and soft-tissue surgery but also bone cutting, shaving, recontouring and resection. Convergent Dental is showcasing Solea at ADA 2015 in Washington, D.C. from November 5-10, 2015.

Solea’s osseous tissue clearance is said to allow dentists to perform procedures ablating bone with speed, precision and less bleeding. As a result, patients may experience less post-operative discomfort and faster healing times. These benefits are designed to improve the patient experience, reduce chairtime and increase the economic impact for a dental practice.

Related reading: Convergent Dental unveils new 8/400, 8/600 and 8/1200 Hollow Waveguides at CDA Presents Anaheim 2015

“Convergent Dental’s rapidly expanding clinical indications for Solea is another example of their commitment to innovation,”  Dr. Simon Bernstein said. “With this new osseous tissue clearance by the FDA, Solea’s unique 9.3-micron wavelength continues to create the opportunity for minimally invasive dentistry.”

“This osseous tissue clearance is a critical component of our long term grow strategy. It adds even greater value for our current customers who can add more procedures to their repertoire and makes Solea a compelling option for specialists including periodontists and oral surgeons,”  Convergent Dental CEO Michael Cataldo said.

Convergent Dental ‘s focus on continuous innovation has made it the fastest growing all-tissue dental laser company in the United States. Practitioners interested in learning more about Solea and its latest FDA clearance for osseous tissue procedures can email info@convergentdental.com or call 1-844-GO-SOLEA.

More on Convergent Dental: Convergent Dental partners with Benco Dental

Related Videos
CDA 2024 Video Interview with Kuraray Noritake's Dinesh Weerasinghe and Richard Young, DDS
2024 Dental Products Report Spring Selection Bracket Reveal Video
2024 Chicago Dental Society Midwinter Meeting – Interview with Peter Maroon, business development and sales lead at Spectrum Solutions® on the new salivary diagnostic test, SimplyPERIO.
Product Bites – March 8, 2024 Part 2
Product Bites – March 8, 2024 Part 1
Contemporary Cosmetic Dentistry – Part II: Arresting Marginal Caries
GNYDM23 Product Focus: CandidPro with Kristin Lange, VP of Sales at Candid
Greater New York Dental Meeting 2023 – Interview with Suzanne Cano from LunaLite Dental
Greater New York Dental Meeting 2023 — Interview with Shannon Carroll, RDH
© 2024 MJH Life Sciences

All rights reserved.